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ABSTRACT 
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to arrive at specific prevalent diseases in India and identified 24 pharmaceutical firms making drugs for these diseases. 
We used data envelopment analysis (DEA) approach to find out the efficiency of firms and peers of inefficient firms. Tobit 
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INTRODUCTION  
India is rapidly growing to become a major and vibrant economic power, in spite of the wide disparities within its social 
milieu. There is increase, also in population of higher income group, who do not hesitate to afford branded costlier drugs in 
preference to cheaper alternatives (FICCI – Ernst & young study, 2010). India is now becoming a lucrative destination for 
global pharmaceutical giants. It is estimated that India may become a US$ 8 billion drug market by 2015 for the MNCs. 
Domestic pharmaceutical market is expected to touch USD 21 billion by 2015, from 7.1 billion in 2007 
(www.moneyexpress.com/ business/33701.txthtml). 
The management of pharmaceutical business includes marketing, quality assurance, R&D, finance, operations, wholesale 
and drug store management. The application of drug laws and/or intellectual property rights will be of necessary use for 
those in pharmaceutical business. Recent developments in pharmaceutical sector in India reveal many mergers and 
acquisitions (M&A) taking place, resulting in shooting up of revenues of the business. The Indian companies are getting 
involved in this M&A space as there is growing domestic market for cheaper versions of patent drugs. (i.e. generic drugs) 
which also will be able to serve developed markets abroad. Unlike in past, the Multi National Companies (MNCs) 
pharmaceutical companies are clearly shifting their strategies:- from giving out manufacturing contracts to Indian 
companies to owning them. Multi National Companies (MNCs) are attracted by the emerging markets in Indian scenario 
for generic drugs. This trend is noticed in the strategy of companies such as Pfizer, GSK, Abott and Sanofi. The 
pharmaceutical market has witnessed a strong double – digit growth ranging from 13.5 % to 17 % over the past four years 
(with the exception of the year 2008 when growth was relatively low at 10 %). So for those MNCs facing sluggish sales in 
their home markets, even a market share of 2-3 % in India could be attractive. (Mergers & Acquisitions in Pharmaceutical 
industry- News report Times of India:16.02.2011). Some of M&A in pharmaceutical industries are shown in Table-1. 
The tendency of Indian pharmaceutical majors being bought by MNCs orients them away from Indian markets, and it may 
have adverse effect on drug pricing and affordability on the part of the average Indian consumer. In last four years, at least 
six big acquisitions of this kind took place. 
Table-1 Mergers and Acquisitions in Pharmaceutical Industries: 
Year Indian Company taken over Foreign Buyer Deal size $ Million 
June'08 Ranbaxy Lab Daiichi Sankyo,Japan 4600 
July'08 Shantha Biotech Sanofi Aventis, France 783 
Dec'09 Orchid  Hospira, USA 400 
Aug'06 MatrixLab Mylan Inc. 736 
May'10 Piramal Healthcare Abott, USA 3720 
Dec'10 Paras Pharma Reckitt Benckiser, USA 726 
(source: Mergers & Acquisitions in Pharmaceutical industry- News report Times of India :16.02.2011: “Pharma sector 
injects fresh life into M &A space) 
The biosimilar opportunity is also big, that big pharmaceutical giants don’t want to miss it. Merck has established a 
subsidiary and Pfizer has tied up with Biocon. A biosimilar is approximate copy of a patented biological drug. It is 
approximate copy because it is hard or impossible to make an exact copy of a biological at the moment. While generic 
drugs have made a big dent in the market, regulators had not allowed generics companies to make off-patent biological. 
They are relaxing their attitudes due to the high cost of patented biologicals. As in the generics, Indian companies are 
looking at a large global market in biosimilars. Big opportunity for Indian firms as several blockbusters goes off patent 
during year 2017 -2024. The size of the biosimilars market by 2020 is expected to be $ 11 Billion (: Economic Times, 1st 
March 2012). 
In view of above discussed scenario, it is quite obvious that costly drugs, which are ordinarily beyond the reach of average 
Indian consumer and which are manufactured by pharmaceutical companies including MNCs, are still reigning the market 
and enjoying their share in a tough competitive market. Nevertheless, keeping larger public good in mind, it will be in the 
best interest of even these companies to tailor down their costs to meet needs of consumer,without any compromise on 
quality. Keeping wide spectrum of prevalent diseases in India in view, analysis may be conducted to assess the firms in 
making available of vital drugs on basis of certain criteria such as: 
1. Generic formulations of single drugs or generic formulations of scientifically acceptable and rational 
combinations. 
2. Assessment of these firms spends on R&D which eventually increases the cost of medicine. 
3. Analyze if efficient firms are cost efficient. As cost efficient firm can provide drugs at affordable price. 
4. Increase in marketing efforts by the firms supposedly improves the accessibility of drugs. 
By such a study, it may be possible to understand clear picture of comparative assessment of the market place economics 
of drugs and of different firms at large to help the consumers. Like with improved cost efficiency may lead to scope of 
reduction of price. 
Previous Studies 
A number of studies have been published on different aspects pertaining to pharmaceutical firms. Some of the work done 
by authors throws lot of insights on pharmaceutical industry scenario in Indian context.  Kotwani et.al. (2007) studied on 
prices & availability of common medicines at six sites in India.  Sengupta (2010) worked on National Health System in 
India with regards to access to Health Care and Medicines. His work provided detail framework and policy pertaining to 
Indian pharmaceutical industry. 
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Sampath (2005) provided studies on “Economic Aspects of Access to Medicines after 2005: Product Patent Protection and 
Emerging Firm Strategies in the Indian Pharmaceutical Industry”. Dhar & Gopukumar (2006) provided detailed information 
on Post-2005 Trade Related Aspects of Intellectual Property Rights (TRIPS) scenario in patent protection in the 
pharmaceutical sector in particular to generic pharmaceutical industry in India. Kiran Ravi & Mishra Sunita (2011) also 
provided a post TRIPS analysis on pharmaceutical companies. 
Some of the papers published based on financial statement analysis of the firms. We are focusing mainly on those studies 
that use frontier analysis or DEA to gauge performance of pharmaceutical firms.  
Pannu et.al. (2010) studied on aspect of Innovation on performance of Indian Pharmaceutical Industry. Malhotra & 
Malhotra (2008) used DEA where it employs relative efficiency, a concept enabling comparison of companies with a pool 
of known efficient companies. The inputs considered are “days of sales outstanding, days cost of goods, sold in inventory, 
total debt/equity. The outputs considered are “cash flow per share, return on equity, return on assets, return on invested 
capital, inventory turnover, interest rate coverage, quick ratio”. Saranga (2007), Saranga and Phani (2004) used DEA to 
study the performance of pharmaceutical companies in order to determine the best practices in the Indian Pharmaceutical 
industry. Mazumdar et.al. (2010) used DEA efficiency score of a firm which provides an assessment of its performance 
based on measurement of output and input efficiencies for Indian pharmaceutical firms. 
Identification of prevalent disease in India 
Delphi Technique is used to arrive at specific prevalent diseases in India. Delphi technique used to form consensus after 
opinions from experts for specific prevalent diseases in Indian context. Study on these firms was arrived based on drugs 
(generic names) and older (Innovator) drugs, specific against the diseases, available in market. 
The Delphi technique was developed during the 1950s by workers at the RAND Corporation while involved on a U.S. Air 
Force sponsored project. The aim of the project was the application of expert opinion to the selection – from the point of 
view of a Soviet strategic planner – of an optimal U.S. industrial target system, with a corresponding estimation of the 
number of atomic bombs required to reduce munitions output by a prescribed amount. More generally, the technique is 
seen as a procedure to ‘‘obtain the most reliable consensus of opinion of a group of experts . . . by a series of intensive 
questionnaires interspersed with controlled opinion feedback’’ (Dalkey & Helmer,1963). Delphi technique was earlier used 
for futuristic study, but currently it is being used extensively in social sciences to arrive at a consensus by a panel of 
experts (Chia & Sandford, 2007). 
We used Delphi technique with a panel of seven judges, working at a distance, with all communication by email through a 
moderator. There are two separate stages, shortlisting and judging, each consisting of an initial round that elicits panelists’ 
comments on the entries, followed by three rounds in which panelists nominated their preferred entries. The number of 
rounds depends on how quickly a consensus emerges. 
Panelists sent their responses to the author who was the moderator, which was collated and circulated to them 
anonymously after each round, as the basis for the next round. The panelists have at each stage a full record of what 
comments and nominations other panelists have made, but they do not know who made which comment or voted for 
which entry. Nor do they know the final result, till the same was disclosed after the consensus which was reached after 3 
rounds for the widely prevalent diseases in Indian context fit for the studies. The following diseases and the relevant drugs 
are being considered for study out of the exhaustive list of widely prevalent and emerging diseases in Indian population. 
This study is further based on following diseases supported by expert opinion of Medical professionals as selected by the 
process cited above:- 
Communicable diseases: 
Tuberculosis  
The treatment of Tuberculosis, world over, is based on WHO guidelines, according to which the first line drugs (categories 
I, II & III) for routine cases and second line drugs, which are given in drug-resistant cases i.e multi drug resistant 
tuberculosis (MDRTB) (source: 1. TB-A clinical manual for South -east Asia: Harries et.al., World Health Organization 
(WHO), Geneva,1997,  2. Guidelines for the management of drug- resistant Tuberculosis Crofton et.al.WHO, 
Geneva,(1997) 
The treatment of the disease is done based on the category of patient affected by the infection. The treatment can be 
done based on administration of First line Drugs or 2nd Line drugs for MDRTB, as the case may be. The list of I st Line 
drugs and manufacturers is provided in Table -2. Similarly for 2nd line drug is illustrated in Table-4. 
Human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS)  
Anti Retroviral drugs used for treatment of HIV-AIDS is provided in Table 3. 
Non communicable diseases 
Diabetes mellitus  
The treatment for Diabetes based on the severity is done through administration of oral hypoglycemic agents as Shown in 
Table-5. The treatment done through administration of Biguanides and its combinations are provided in Table-7. Table-6 
provides the list of companies into different types of Insulin used for treatment of Diabetes. 
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Table-2 – 1st line drugs for Tuberculosis and Medicine Company name 
 
(Source: Industry Drug Review) 
Table-3. Antiretroviral drug for HIV/AIDS 
 
 
Disease
Medicine Rifamycin 
(RIFA)
Isonicotonic acid 
Hydrazide (INH)
Pyrazinamide 
(PZA)
Etham butanol 
(ETB)
ETB + INH RIFA + INH RIFA + INH 
+PZA
RIFA + INH +PZA 
+ ETB
Streptomycin 
(injectible)
Company 
name
Aristo Park Davis Novartis Lupin Lupin Unichem Novartis Novartis SPPL-Ethical 
Div
Lark Labs Albert David Macleods Macleods Plethico Ovearseas HC Unichem Larks Lab
Lupin IPCA Lark Labs RPG lifesciences Cadilla Pharma Biological E Biological E Lupin
Macleods Pfizer Taurus Panacea Biotech Le Sante Merind Platheco Unichem
Plathico Macleods Lasante Samarth Pharm Themis Aristo Merind Biological E
Concepts Overseas HC Concepts Alkem Aristo Merind
IDPL PCI Emcure Zydus Cadilla Alkem Alkem
Le Sante Emcure Pharmed Emcure Emcure Zydus Cadilla
Overseas HC Aristo Plethico IDPL Lark Labs Macleods
Biochem Le Sante Larks Labs Lark Labs IPCA Platheco
Zydus Cadilla Pharmed Le Sante IPCA Macleods Le Sante
Novartis Lupin Overseas HC Biochem Le Sante Suniz
Themis Novartis Taurus Labs Pharmed Lupin Overseas HC
Taurus labs Themis Themis Macleods Suniz Indoco
Taurus Platheco Overseas SC Concepts
GSK Concept Themes
Indoco Rextar
Aventis Wockhardt
Kresp GSK
Novartis
Pharmed
Rextar
Themes
GSK
Tuberculosis (Ist line drugs)
Disease
Medicine Zidovudine 
(ZDV)
Abacavir (ABC) Didanosine 
(ddi)
Emtricitabine 
(FTC)
Lamivudine 
(3TC)
Stavudine (d4T) Tenofovir 
(TDF)
Company 
Name
GSK Cipla Cipla GSK Cipla
Cipla Zydus Biogen
Le Sante Zydus Alidac
Samarth Pharma La Sante
BHB lifesciences
Zydus Biogen
Medicine Amprenavir 
(APV)
Atazanavir 
(ATV)
Darunavir Fosamprenavir 
(FPV)
Indinavir 
(INV)
Lopinavir (LPV) Nelfinavir Ritonavir (RTV) Saquinavir 
(SQV)
Tripanavir 
(TPV)
Company Cipla Cipla Cipla
Genix Pharma Genix Pharma
Medicine Efavirenz (EFV) Nevirapine 
(NVP)
Delavvirdine 
(DLLV)
Company Cipla La Sante
Cipla
AIDS (HIV +) Antiretroviral drug (ARV)
1. Nucleoside reverse transcriptase inhibitors (NRTI) (Nucleoside Analog)
2. Protease Inhibitor (PI)
3. Non nucleoside reverse transcriptase inhibitor (NNRTI) effective for HIV-1 & HIV-II
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Table-4.  2nd Line drugs for Multi drug resistant Tuberculosis and company name 
 
 
 
Disease
Medicine Amikacin Ciprofloxacin Ofloxacin Kanamycin Paraminosalicylic 
acid (PAS)
Ethionamide Prothionamide Cycloserine Capriomycin Clofazimine
Company 
name
Cadilla Pharma Sarabhai Anichem Labs Macleods Macleods Lupin Le Sante Macleods Macleods Atra Zeneca
NPIL Alkem Aquilla Labs Samarth Pharma Lupin Overseas HC Macleods Lupin SPPL
Neon labs Aquilla Bestochem Alembic USV limited Themes Themis BHB pharma
Biochem Otsira genetica Kee Pharma Macleods Panacea 
Comed Bayer Biochem BHB Lifesciences Samarth
Lupin NPIL Biodrug Le Sante
Indoco Biochem Claris 
Lifesciences
Panacea Biotech
Samarth Pharma Plathico Divus Labs Samarth Pharma
Alkem Blue Cross Mimec pharma
Indswift Memec Pharma Ethicare
Plathico Warren Medico labs
Global Medical 
sciences
Eglomed Emcure
Brown and Burk Ranbaxy Dey's 
Syntheko Albert David Neu Foreva
Mapra Lab Biological E MarK remedies
Aristo Anichem Labs Zenith HC
Troikaa Cipla Merind
Emcure Indoco Monochem
Novamed Core e Merck
Secure HC Zydus Cadilla Brussels
Taurus Emcure Seagull Labs
Cachet Cadilla Pharma Blue Cross
Glenmark Khandelwal
Lark Labs Concepts
Dr. Reddy's Labs Oglamed
Lupin Pharma Zydus Cadilla
Alembic Macleods
Claris 
Lifesciences
Suniz Pharma
Mankind Medley Pharma
Sun Pharma Emcure
GSK Aventis
Macleods Vales
Concept Indswift
Dey's Taurus Lab
HAL (Hindustan 
Antibiotic limited)
Balpharma
Formed Mankind
Karnataka 
Antibiotic ltd 
(KAPL)
FDC
NPIL Stancare
Biddle Sawyer
Torrent
Dabur
Hygeia
Khandelwal
Indswift
Taurus
Balpharma
Wyeth Laderly
FDC
Tuberculosis (2nd line drugs for Multi drug resistant Tuberculosis (MDRTB))
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Table-5 – List of Oral Glycemic Agents used for treatment of Diabetes Mellitus 
 
Table-6 List of company making Insulin for treatment of Diabetes  
 
(Source: Drug Today) 
 
 
Disease
Medicine Chloropropamide Tolbutamide Glibenclamide Glipizide Gliclazide Glimepride Rosilglitazone 
+ Glicazide
Rosilglitazone Pioglitazone
Company Dey's Pharma Cadilla Pharma Emcure Torrent Aventis Aristo Torrent (psycan) Biochem
Zydus Medica Bal Pharma Comed Torrent Dr. Reddy's Lab Unisearch
Sarabhai Microlabs Bal Pharma Panacea Sun Pharma Medley
Aventis Otsira Genetica Serdia BioChem Aristo Indswift
Inga Franco Indian Carsyon Microlabs Healtheon Zydus Medica
NPIL Modi Mundi Pharma RPG Lifesciences Emcure Microlabs Panacea
Bal Pharma RPG lifesciences Argus Medley RPG Lifesciences Wockhardt
Sun Pharma Alembic Inga Argus Emcure Healtheon
USV Wallace Alkem Comed Systopic
Otsira Genetica Jenburkt Khandelwal RPG Lifesciences Ranbaxy
USV Modi Mundi Pharma Otsira Genetica Sun Pharma
Stadmed JKDPL Ranbaxy Emcure
Dey's Stadmed Wallace KAPL
Panacea Sun Pharma Alembic
Raptakos Cadilla Pharma Intas
Medley Win Medicare Life Medicare
Indoco Kopran Comed
Aristo Bal Pharma Karsyon
IPCA Life Medicare Balpharma
USV Intas Otsira Genetica
Protec Aglomed
Cadilla Pharma RPG 
Lifesciences
Novartis Kopran
Alembic Argus
Jagsonpal IPCA
Dey's Indoco
Intas NPIL
Dr.Reddy's labs Franco Indian
Cadilla Pharma
E.Merck
Diabetes mellitus (Oral Hypoglycemic agents)
1. Sulphonyl ureas
Disease
Medicine
Neutral  Insulin 
(Soluble)
Isophane Insulin 
(NPH)
Insulin Zinc suspension 
(Lente Insulin)
Pre mixed 
biphasic Insulin
Insulin Lispro Insulin Glargine
Company Novo Nordisc Biocon Novo Nordisc USV Eli lily Aventis Pharma
USV USV Eli-Lily Novo Nordisc Ranbaxy
Sarabhai Novo Nordisc Ranbaxy Sara Bhai
Eli lily Sara Bhai Sarabhai Eli-lily
Ranbaxy Eli-lily Cadilla Pharma Ranbaxy
Aventis Aventis Aventis
Cadilla Pharma IRM Pharma Cadilla Pharma
Diabetes mellitus (Insulin)
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Table-7 List of company making Biguanides for treatment of Diabetes 
 
From the above work we came across 87 pharmaceutical firms relevant for the study. The data was collected from the 
Annual report of companies and was also gathered from Bloomberg, Mar, 2013. 
 “Many companies manufacturing or distributing a range of products will find that the Pareto Law will apply and can be 
exploited to determine supply strategy. Typically an analysis of the business will show that the 80/20 (or similar) rule holds. 
In other words, 80% of total volume will be generated from just 20% of the total product line.”( Martin Christopher and 
Denis Towill (2001). Considering the above stated Pareto’s approach we have considered 24 pharmaceutical firms which 
contribute to more than 80 % of the business. We could get the data for 24 companies which are listed in stock exchange 
and for those companies whose websites were having the Annual report for the year 2012. 
Data Envelopment Analysis (DEA) 
Data Envelopment Analysis (DEA) is a non-parametric method of measuring efficiency of any Decision Making Unit (DMU) 
like firms, retail stores, public sector agency etc (Ramanathan, R. (2003). It was first introduced into the operation 
research by Charnes, Cooper and Rhodes in 1978 which is known as CCR model. This model has an assumption of 
constant returns to scale. Then, in 1984, Banker, Charnes and Cooper introduced a new model, known as BCC model. 
This model was an extension of the CCR model to accommodate the variable return to scale into consideration while 
analyzing the efficiency or performance of any DMU.  
CCR model takes n DMUs into consideration, using m inputs to secure s outputs. The notations which are used in the 
model are as follows- 
m: number of inputs  (i=1,2,…m) 
Medicine Phenphormine Metphormine Metphormine + 
Glibenclamide
Phenphormine 
+ 
Chlorpropamid
Metphormine 
+ Glipizide
Metphormine + 
Gliclazide
Metphormine + 
Glimpride
Metphormine + 
Rosiglitazone
Metphormine + 
Pioglitazone
Company USV Ostira Genetica RPG Lifesciences adilla Phar a Nucron Pharma Torrent Novartis Torrent Unisearch
Aventis NPIL Bal Pharma Comed Torrent Aztec Stancare
Argus USV Novartis Bal Pharma Panacea Aristo Sunpharma
CFL Bal Pharma Microlabs Carsyon Otsira Genetica Healtheon Emcure
Torrent Sun Pharma Franco Indian Argus Cadilla Pharma Panacea Intas
Bal pharma Modi Mundi Pharma Aztec Alkem NPIL Microlabs Carsyon
Novarts Win Medicare Zenburkt Biochem Unisearch Emcure Otsira genetica
Stadmed NPIL USV Khandelwal Intas NPIL
IPCA Argus Dey's Pharma Modi Mundi 
Pharma
Cadilla Pharma
Dey's Otsira Genetica Win Medicare
Alkem Taurus Labs Stadmed
Alembic Tridoss Panacea
NPIL Raptakos
Protec Medlay Pharma
Franco Indian Indoco
Emcure Aristo
Cadilla Pharma IPCA
Microlabs Cipla
Comed Mankind Pharma
Panacea Cadilla Pharma
Zenburkt Novartis
PIL Alembic
Ranbaxy Dey's
RPG lifesciences Jagsonpal
Wallace Intas
Healtheon Dr. Reddy Labs
Raptakos Wallace
Intas PIL
Medicine Acarbose Repaglinide Nateglinide
Emcure Torrent Healtheon
Wockhardt Azitec (Sun) Alembic
Cardicare Wallace Intas
Balpharma Emcure
Otsira Genetica
Healtheon
Medley
Arian, Sun
Biguanides and it's combinations
Others
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s: number of outputs (r=1,2,…s)  
n: number of DMUs (j=1,2,…n) 
xij : i
th
 input of j
th
 DMU 
yrj:  r
th
 output of j
th
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














mnmm
n
n
xxx
xxx
xxx
...
......
...
...
21
22221
11211















snss
n
n
yyy
yyy
yyy
...
......
...
...
21
22221
11211
 
u = (u1,u2,….us)               v = (v1,v2,….vm) 
The efficiency of each DMU is measured once and hence we need n optimization problem to be solved, one for each 
DMUj. Let the DMUj to be evaluated on any trial be designated as DMUo, where“o”ranges over 1,2,….,n. We solve the 
following LP to obtain values for the input weights v1,v2,….vm and output weight u1,u2,….us as variables. 
max u1y1o + u2y2o + …… + usyso 
s.t. v1x1o +  v2x2o + ...... + vmxmo = 1 
 u1y1j + u2y2j + .... + usysj  ≤ v1x1j +    v2x2j + ...... + vmxmj      (j = 1,2,....,n) 
 v1,v2,….vm  ≥ 0 
 u1,u2,….us   ≥ 0 
The dual of LP helps in recognizing the reference set for the inefficient DMUs. These reference sets then help us in 
identifying the inadequacies existing in the inefficient units. The dual of the above model can be given in the following 
form- 
min θ = θ* 
s.t. Yλ ≥ yo 
 Xλ ≤ θxo        
 λ ≥ 0 
The BCC model differs from the CCR model only in the adjunction of the condition 1
1


n
j
j  which we also               
write e  = 1 where e is a row vector with all elements unity and λ is a column vector with all elements non-negative.  
 
The above model provides technical efficiency (θ) of any DMU.  
Phase – I 
Min θ = θ* 
s.t. Yλ  ≥  yo 
 Xλ  ≤  θ xo      
eλ   =  1    
λ ≥ 0 
We solve phase-I to get θ*. Then using our knowledge of θ*, we solve phase-II. 
Phase-II 
Min ∑ s i
-
 - ∑ s r
+
 
s.t.    
Yλ - s r
+
 = yr0 ,    r =1,2,3, …. s 
Xλ + s i
-
 = θ*xi0 , i =1,2,3, …. m 
eλ   =  1 
λ ≥ 0, s i
-  
, s r
+ 
≥ 0 
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Data Variables 
The variables selected for the study are categorized as input-output in the following manner 
Inputs 
The inputs considered are Expenditure on Research and development (R&D), Cost of Materials, Weighted Average cost 
of capital (WACC). 
To state, “Without a dramatic increase in R&D productivity, today’s pharmaceutical industry cannot sustain sufficient 
innovation to replace the loss of revenues due to patent expirations for successful products.” (Paul et.al, 2010,). 
Expenditure on Research and Developments (R&D) is needed for innovation and considered as a key input.  
Cost of materials (CM) is the cost of the raw materials consumed to make the finished goods. 
The cost of capital is a standard tool of practical finance, so it's worth writing out the formula. Let rD, and rE, be the cost of 
debt and the cost of equity-that is, the expected rates of return demanded by investors in the firm's debt and equity 
securities. The overall (weighted-average) cost of capital depends on these costs and the market-value ratios of debt and 
equity to overall firm value. 
Weighted Average Cost of Capital = rA, = rD,D/V + rE,E/V 
The weighted average cost of capital rA, is the expected return on a portfolio of all the firm's outstanding securities. (Myers, 
2001). 
A calculation of a firm's cost of capital in which each category of capital is proportionately weighted. All capital sources - 
common stock, preferred stock, bonds and any other long-term debt - are included in a WACC calculation. All else equal, 
the WACC of a firm increases as the beta and rate of return on equity increases, as an increase in WACC notes a 
decrease in valuation and a higher risk. The WACC equation is the cost of each capital component multiplied by its 
proportional weight and then summing: 
Weighted Average Cost Of Capital (WACC) 
 
Where: 
Re = cost of equity, Rd = cost of debt, E = market value of the firm's equity, D = market value of the firm's debt,  
V = E + D, E/V = percentage of financing that is equity, D/V = percentage of financing that is debt, Tc = corporate tax rate 
Businesses often discount cash flows at WACC to determine the Net Present Value (NPV) of a project, using the formula: 
NPV = Present Value (PV) of the Cash Flows discounted at WACC. 
Outputs 
Outputs are Sales in million INR, Net Profit, Earning per Share (EPS), Export %  
Earnings per share (EPS) is the amount of earnings per each outstanding share of a company's stock.The portion of a 
company's profit allocated to each outstanding share of common stock. Earnings per share serves as an indicator of a 
company's profitability. 
                  (   )  
                                       
                         
 
When calculating, it is more accurate to use a weighted average number of shares outstanding over the reporting term, 
because the number of shares outstanding can change over time. However, data sources sometimes simplify the 
calculation by using the number of shares outstanding at the end of the period. Diluted EPS expands on basic EPS by 
including the shares of convertibles or warrants outstanding in the outstanding shares number. 
We are dropping Sales from output as Sales and Profit are highly correlated as stated in Table-8. 
Table-8.  Correlations of outputs  
  O1 Sales O2 Profit O3 Earning  / Share O4 Export 
O1 Sales  
1   
 
 
O2 Profit  
.776
**
 1  
 
 
O3 Earning / Share  .201 .219 1  
O4Export  .040 .009 .007 1 
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The descriptive statistics for the outputs and inputs considered are presented in Table 9. The efficiency of DMUs, their 
peers, possible reductions of inputs in percentage, possible increase in outputs in percentage are presented in Table 10. 
Table-9  Descriptive Statistics of outputs and inputs 
 N Minimum Maximum Mean Std. Deviation 
Profit  24 9 25873 4866.75 5802.790 
Earning per Share  24 .51 76.76 26.0029 19.99184 
Export  24 2.73 86.90 33.0217 21.15355 
R&D  24 3 6243 1591.67 1920.518 
CM  24 314 23264 9167.79 7705.955 
WACC 24 6.34 10.82 9.3254 .86017 
Valid N (listwise) 24     
Table 10 Efficiencies, Peers and Projections 
 
In order to clearly examine the determinants of efficiency, we further applied Tobit regression model regressing the BCC 
efficiency (as shown in second column of Table 10) as dependent variable. As per DEA literature Coelli(1998), Tobit 
regression model is suitable when the dependent variable is censored. The Tobit regression model is represented as- 
ii
iiiiiii
WACC
CMDRExportEPSofit




)(
)()&()()()(Pr
6
54321
 
Where, i  is the efficiency score for the pharmaceutical  company, i computed from the BCC model.  
The BCC efficiency statistics are as shown below. 
DMU # BCC effi. Benchmark 
DMU #s
Net Profit (O2) EPS (earning per 
share) (O3)
Export % (O4) R&D Spent (I1) Cost of Material, 
cogs (I2)
Weighted Average cost 
of capital WACC (%) (I3)
1 0.73 8,13,19 107 538 0 53 27 27
2 0.85 13,19,21 23 0 360 15 36 15
3 0.75 8,19,22 0 151 0 61 46 25
4 0.87 8,19,22 0 28 0 76 47 12
5 0.98 8,19,22 0 153 0 50 55 1.5
6 0.94 13,21 6 111 21 5 84 5
7 1 0 0 0 0 0 0
8 1 0 0 0 0 0 0
9 1 0 0 0 0 0 0
10 0.89 13,19 19 0 239 11 64 11
11 1 0 0 0 0 0 0
12 0.76 8,19,22 0 152 0 74 66 23
13 1 0 0 0 0 0 0
14 0.9 13,19,21 118 547 0 9 64 9
15 0.91 8,19 43 92 0 56 34 8
16 0.72 8,19 258 74 0 76 42 27
17 1 0 0 0 0 0 0
18 0.94 8,19,22 0 98 0 79 53 5
19 1 0 0 0 0 0 0
20 0.85 19,22 0 76 0 43 60 14
21 1 0 0 0 0 0 0
22 1 0 0 0 0 0 0
23 0.81 8,19,22 0 30 0 73 38 18
24 0.85 0 38 0 82 64 14
Output % to increase Input % to decrease
Phase -I Phase-II
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Table 11: BCC efficiency statistics 
  Minimum Mean Maximum SD 
BCC efficiency 0.72 0.9062 1.0000 0.09753 
The
2 test statistics (=244.8) with five degrees of freedom associated with p value (= 0.0) shows that the model is a 
good fit for the data. Also we find that the value of constant 2 (e
-2.52
= 0.08046) from the Tobit model is less that the 
standard deviation of i (=0.09753) which again shows that the models appears to fit the data well. The results of Tobit 
regression are presented in Table 12. 
Table 12: Tobit regression model 
Variable Value Std. Error z-value p-value 
Constant 1.6600000 0.27800000 5.95493   
Profit** 0.0000432 0.00001680 2.57840     0.004963 
Earning per Share 0.0003140 0.00134000 0.23538 0.406957 
Export** -0.0022300 0.00123000 1.80903 0.035223 
R&D** -0.0000519 0.00001745 -2.98381 0.004123 
CM** -0.0000112 0.00000701 -1.60411    0.054345 
WACC** -0.0086300 0.03030000 -2.84309    0.002234 
         ** Significant   
Recommendations and conclusions 
DEA was useful to find out the benchmark DMU / companies. It was found that all companies are above 70 % BCC 
efficient. The benchmark companies for each are cited in Table 10. There is a tremendous scope to reduce the R&D 
spent. It can be inferred that even though the spent on R&D is more but it is not yielding enough.  The cost of materials 
also needs to be reduced. The inference is that these firms are using cost plus margin system and there is good scope for 
backward negotiations with the vendor to reduce the cost of raw materials which can help society in large to produce 
drugs at affordable prices. The results derived through Tobit regression analysis highlights that the efficiency of 
pharmaceutical firms is mainly impacted either by output variables namely profit and export or by input variables i.e. R&D 
and WACC.  
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